Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and ImmunotherapyReport as inadecuate




Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy - Download this document for free, or read online. Document in PDF available to download.

BioMed Research International - Volume 2015 2015, Article ID 851387, 16 pages -

Review Article

Department of Dermatology, Sexually Transmitted Diseases and Immunodermatology, Faculty of Medicine, Nicolaus Copernicus University in Toruń, 9 Sklodowskiej-Curie Street, 85-094 Bydgoszcz, Poland

Department of Cardiology and Internal Medicine, Faculty of Medicine, Nicolaus Copernicus University in Toruń, 9 Sklodowskiej-Curie Street, 85-094 Bydgoszcz, Poland

Received 22 March 2015; Accepted 19 May 2015

Academic Editor: Jean Kanitakis

Copyright © 2015 Anna Niezgoda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The incidence of malignant melanoma is increasing. The majority of patients are diagnosed in early stages when the disease is highly curable. However, the more advanced or metastatic cases have always been a challenge for clinicians. The poor prognosis for patients with melanoma is now changing as numerous of promising approaches have appeared recently. The discovery of aberrations of pathways responsible for intracellular signal transduction allowed us to introduce agents specifically targeting the mutated cascades. Numerous clinical studies have been conducted to improve effectiveness of melanoma treatment. From 2011 until now, the U.S. FDA has approved seven novel agents, such as BRAF-inhibitors vemurafenib 2011, dabrafenib 2013, MEK-inhibitors trametinib 2013, anti-PD1 antibodies nivolumab 2014, pembrolizumab 2014, anti-CTLA-4 antibody ipilimumab 2011, or peginterferon-alfa-2b 2011 intended to be used in most advanced cases of melanoma. Nevertheless, clinicians continue working on new possible methods of treatment as resistance to the novel drugs is a commonly observed problem. This paper is based on latest data published until the end of January 2015.





Author: Anna Niezgoda, Piotr Niezgoda, and Rafał Czajkowski

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents